-
Mashup Score: 22Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease - 1 month(s) ago
Objectives A timely diagnosis is imperative for curing cancer. However, in patients with rheumatic musculoskeletal diseases (RMDs) or paraneoplastic syndromes, misleading symptoms frequently delay cancer diagnosis. As metabolic remodelling characterises both cancer and RMD, we analysed if a metabolic signature can indicate paraneoplasia (PN) or reveal concomitant cancer in patients with RMD. Methods Metabolic alterations in the sera of rheumatoid arthritis (RA) patients with (n=56) or without (n=52) a history of invasive cancer were quantified by nuclear magnetic resonance analysis. Metabolites indicative of cancer were determined by multivariable regression analyses. Two independent RA and spondyloarthritis (SpA) cohorts with or without a history of invasive cancer were used for blinded validation. Samples from patients with active cancer or cancer treatment, pulmonary and lymphoid type cancers, paraneoplastic syndromes, non-invasive (NI) precancerous lesions and non-melanoma skin can
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
Metabolic changes in sera of patients with #rheumatoidarthritis or #spondyloarthropathies are indicative of cancer or paraneoplastic syndroms, a new study from 🇩🇪 shows. Will it facilitate an earlier diagnosis of #cancer in this population? 🔗 https://t.co/W0AeMoOb5w https://t.co/pxrQUCSKVJ